Biogen (BIIB) Tops Q3 EPS by 61c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen Reports Quarterly Revenues of $3.1 Billion
October 24, 2017 6:59 AM EDTTotal revenues grew 4% or 13% excluding hemophilia revenues*
GAAP diluted EPS rise 23%; Non-GAAP diluted EPS rise 22%
Company advances its strategic priorities
Company restructures collaboration arrangements with Eisai and Neurimmune to improve long-term value of aducanumab
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Biogen Inc. (NASDAQ: BIIB) today reported third quarter 2017 financial results, including:
Total revenues of $3.1 billion, a 4% increase versus the prior year or a 13% increase excluding hemophilia revenues*. Multiple sclerosis (MS) revenues, including approximately $65... More